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SUMO-1 Modification of Mdm2 Prevents
Its Self-Ubiquitination and Increases
Mdm2 Ability to Ubiquitinate p53
The first is represented by HECT (homologous to E6AP
carboxy terminus) ligases, in which the formation of ubi-
quitin-thioester intermediates is followed by a direct
transfer of ubiquitin onto a substrate (Nuber and Scheff-
ner, 1999), as shown for E6AP, RSP5, and Nedd4 (Hui-
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New York, New York 10029 bregtse et al., 1995; Schwarz et al., 1998). The other E3
class, whose activity depends on the presence of a RING²Department of Biochemistry and Molecular Biology
University of Medicine and Dentistry of New Jersey finger motif, does not form thioester intermediates with
ubiquitin (Chen et al., 2000). Small RING finger proteinNewark, New Jersey 07013
ROC1/Rbx1/Hrt1 mediates ubiquitin ligation within the
multiprotein E3 complexes, such as Skp1-Cullin1-F box
protein-ROC1 (SCF-ROC1) and VHL-elongin B-elongin
Summary C-Cullin2-Roc1 (VCB-Cul2-ROC1) (Kamura et al., 1999;
Tan et al., 1999; Wu et al., 2000). These E3s mediate
Mdm2 is an E3 ubiquitin ligase for the p53 tumor sup- ubiquitination of cyclin-dependent kinase inhibitors,
pressor protein. We demonstrate that Mdm2 is conju- yeast cyclins, inhibitor of NF-kB transcription factor
gated with SUMO-1 (sumoylated) at Lys-446, which is (IkB), b-catenin, and a subunit of hypoxia-inducible fac-
located within the RING finger domain and plays a criti- tor (reviewed in Deshaies, 1999). APC11, a ROC1 homo-
cal role in Mdm2 self-ubiquitination. Whereas mutant log, participates in the formation of the anaphase-pro-
Mdm2K446R is stabilized, it elicits increased degradation moting complex (APC) ubiquitin ligase and mediates
of p53 and concomitant inhibition of p53-mediated ubiquitination of cyclins A and B, Pds1, and Geminin
apoptosis. In vitro sumoylation of Mdm2 abrogates its (reviewed in Zachariae and Nasmyth, 1999).
self-ubiquitination and increases its ubiquitin ligase Whereas ROC1 and APC11 are part of a multiprotein
activity toward p53. Radiation caused a dose- and complex and rely on their partners (i.e., F box proteins)
time-dependent decrease in the degree of Mdm2 for substrate recognition, recent studies reveal a rapidly
SUMO-1 modification, which is inversely correlated growing number of RING finger proteins, which directly
with the levels of p53. Our results suggest that the bind their substrate and exhibit ubiquitin ligase activity.
maintenance of the intrinsic activity of a RING finger Among those are mammalian homologs of seven in ab-
E3 ubiquitin ligase is sumoylation dependent and that sentia, AO7, cCbl/Sli-1, BRCA1, and Mdm2 (Hu et al.,
reduced Mdm2 sumoylation in response to DNA dam- 1997; Honda and Yasuda, 1999; Levkowitz et al., 1999;
age contributes to p53 stability. Lorick et al., 1999).
As an oncogene, Mdm2's transforming potential is
largely attributed to its ability to downregulate the func-Introduction
tions of the p53 tumor suppressor protein. The disrup-
tion of p53 biological activities often seen in humanProteolysis plays an important role in regulating the
tumors is, at least in part, attributed to Mdm2 overex-cell's proliferation, differentiation, and response to
pression. Association of Mdm2 with p53 abrogates p53stress. A delicate balance between protein protection
transcriptional activities (Chen et al., 1995). Moreover,from or targeting for degradation underlies the regula-
Mdm2 has been implicated in the proteasome-depen-tion of proteolysis and determines the duration and mag-
dent degradation of p53 (Haupt et al., 1997; Kubbutatnitude of activities elicited by key regulatory proteins.
et al., 1997). Mdm2 has been shown to target p53 ubiqui-Covalent attachment of polyubiquitin is required for the
tination in vitro and in vivo (Honda et al., 1997; Fuchsefficient degradation of proteins by the 26S proteasome
et al., 1998). Although initially believed to form the ubi-complex (Hershko and Ciechanover, 1998). Conjugation
quitin-thioester intermediate (Honda et al., 1997), Mdm2of the ubiquitin polypeptide is mediated by multiple en-
does not contain the HECT domain. Recent evidencezymatic reactions catalyzed by a single ubiquitin-acti-
suggests that Mdm2 mediates p53 ubiquitination via thevating enzyme (E1), a few ubiquitin-conjugating en-
carboxyl terminal RING finger domain and that Mdm2zymes (E2s), and a large variety of ubiquitin ligases (E3s).
is a bona fide RING finger E3 ubiquitin ligase (Fang etWhereas recognition of substrates by E3 ubiquitin li-
al., 2000; Honda and Yasuda, 2000).gases dictates the specificity of protein ubiquitination,
The ubiquitination of p53 by Mdm2 is tightly regulatedthe intrinsic ubiquitin ligase activity represents a rate-
in mammalian cells. Mdm2 effects on p53 are attributedlimiting step of ubiquitin conjugation. Therefore, the
to the abundance of Mdm2 expression, the levels ofmechanisms underlying the regulation of E3 are central
Mdm2-p53 association, and modulation of Mdm2 ubi-to the control of proteasome-dependent protein degra-
quitin ligase activity. Mdm2 levels are regulated by itsdation in vivo.
substrate p53, which activates Mdm2 gene transcriptionTwo major classes of E3 ubiquitin ligases are known.
(Barak et al., 1993). Stabilization of p53 in response to
stress and DNA damage is due to Mdm2 dissociation³ To whom correspondence should be addressed (e-mail: ronaiz01@
from phosphorylated p53 (Shieh et al., 1997; Silicianodoc.mssm.edu).
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p53 may be also attributed to the inhibition of Mdm2
ubiquitin ligase activity upon its association with p14ARF
or MdmX (Kamijo et al., 1998; Honda and Yasuda, 1999;
Sharp et al., 1999).
Mutations of conserved cysteine residues or deletions
in the Mdm2 RING finger domain abolish its ability to
target p53 ubiquitination and prolong Mdm2's half-life
(Fang et al., 2000; Honda and Yasuda, 2000). Since
Mdm2 is capable of self-ubiquitination (Honda and Ya-
suda, 1999) and is degraded by the proteasome pathway
with kinetics that are similar to those of p53, it is unclear
how the intrinsic ubiquitin ligase activity of Mdm2 may
be preserved during p53 ubiquitination. Such a mecha-
nism would be expected to distinguish between Mdm2
self-ubiquitination and the ubiquitination of its NH2-ter-
minal associated protein, p53.
The sidechains of lysil residues serve as a conjugation
site for ubiquitin, as well as for the small ubiquitin-like
modifier protein SUMO-1 (Johnson et al., 1997; Kamitani
et al., 1997). Covalent attachment of SUMO-1 (also
termed Sentrin, Ubl1, or, in yeast, Smt3) to lysines was
demonstrated for the RanGAP1 (Ran GTPase activating
protein1) (Mahajan et al., 1997), IkBa (Desterro et al.,
1998), PML (Kamitani et al., 1998), and p53 (Gostissa et Figure 1. SUMO-1 Is Conjugated to Mdm2 In Vivo
al., 1999; Rodriguez et al., 1999). SUMO-1, which is 18%
(A) Whole cell extracts (WCE) prepared from normal human fibro-
identical to ubiquitin, utilizes a similar conjugation path- blasts were immunoprecipated (IP; 500 mg) with monoclonal anti-
way consisting of activation by a heterodimeric Aos1- bodies either to Mdm2 or to SUMO-1 and analyzed by immunoblot-
ting with the indicated antibodies.Uba2 activating enzyme (E1) and conjugation onto a
(B) 293T cells were transfected with Flag-Mdm2 and HA-SUMO-1.substrate by Ubc9 (Johnson and Blobel, 1997; Johnson
WCE prepared 24 hr later were immunoprecipitated using mono-et al., 1997), a protein with a strong sequence similarity
clonal antibodies against Mdm2 and analyzed by immunoblotting
to ubiquitin-conjugating enzymes (E2s). Unlike ubiquitin, using monoclonal antibodies to HA or to Flag as indicated in the
SUMO-1 does not conjugate to itself and thus is not figure. Right part of the figure depicts the expression level of the
transfected constructs.capable of forming chains similar to the polyubiquitin,
which are required for recognition by the 26S pro-
teasome.
Results
Although SUMO-1 is an essential gene in Saccharo-
myces cerevisiae, the function of SUMO-1 modification Mdm2 Is Conjugated with SUMO-1 in Human Cells
(sumoylation) is not well understood. SUMO-1 conjuga- Analysis of Mdm2 expression by immunoblotting often
tion is implicated in altering the subcellular localization reveals multiple forms that are detected by different
of its RanGAP1, Sp100, and PML substrates (Mahajan Mdm2 antibodies. To test whether some of these forms
et al., 1997; Duprez et al., 1999; Strensdorf et al., 1999), could result from SUMO-1 modification of Mdm2, we
in regulating septin ring dynamics during the cell cycle monitored the possible presence of SUMO-1-conju-
in budding yeast (Johnson and Blobel, 1999), and in gated Mdm2 in vivo. For this purpose, we immunopre-
neural differentiation in Drosophila (Lehembre et al., cipitated Mdm2 or SUMO-1 from denatured normal hu-
2000). Sumoylation of p53 is believed to increase its man fibroblast cell lysates (to inhibit the activity of
transcriptional activities (Gostissa, et al., 1999; Rodri- desumoylation enzymes) and analyzed the samples by
guez et al., 1999). SUMO-1 has an entirely different effect immunoblotting with the monoclonal antibodies against
on IkBa, where it becomes attached to the major ubiqui- Mdm2 and SUMO-1. Of the two major Mdm2-antibody-
tination site (Lysine 21; Desterro et al., 1998), thereby reacting bands (with apparent molecular weight of 75
preventing ubiquitination and protecting sumoylated and 90 kDa; Figure 1A, lane 1), only 90 kDa protein was
IkBa from proteasome-dependent proteolysis. recognized by SUMO-1 antibody (Figure 1A, lane 4).
RING finger domains in E3 ubiquitin ligases were dem- SUMO-1 conjugation with Mdm2 was confirmed by a
onstrated to recruit E2 ubiquitin-conjugating enzymes reciprocal experiment in which proteins were first immu-
(Lorick et al., 1999; Chen et al., 2000). The facts that Ubc9 noprecipitated with Mdm2 antibody and analyzed in
is highly homologous to ubiquitin-conjugating enzymes, Western blot with the SUMO-1 antibody (Figure 1A, lane
that Mdm2 binding partner p53 is sumoylated, and that 2). These data demonstrate that endogenous Mdm2 with
one of the critical sumoylation sites of PML is located an apparent molecular weight of 90 kDa is conjugated
within its RING finger domain prompted us to examine with SUMO-1. The change in mobility of sumoylated
the possibility that Mdm2 serves as a substrate for Mdm2 revealed an z15 kDa shift, which suggests that
SUMO-1 conjugation. Here, we demonstrate that Mdm2 Mdm2 modification can be attributed to the conjugation
is sumoylated and that Mdm2 stability and ligase activity of a single SUMO-1 molecule.
To confirm this finding, we transfected 293T cells withare altered as a consequence of SUMO-1 conjugation.
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Flag-tagged Mdm2 and HA-tagged SUMO-1 constructs.
In these cells, we found that all detectable exogenous
Mdm2 was of z90 kDa (Figure 1B, right panel). Analysis
of Mdm2 immunoprecipitates by HA antibody clearly
showed that Mdm2 is conjugated with HA-SUMO-1 (Fig-
ure 1B, left panel).
Lys-446 Is Required for Mdm2 Sumoylation
The major lysine residue for SUMO-1 conjugation in PML
protein is Lys-65, the fifth residue distal to the beginning
of the first loop of the RING finger (Kamitani et al., 1998).
Comparison of the RING finger motifs of PML and Mdm2
revealed the presence of a similarly distanced Lys-446
within the RING finger of Mdm2. Analogously located
lysines are found in other RING finger proteins, including
murine Mdm2 (K444), equine Mdm2 (K446), BRCA1
(K32), Praja1 (K359), and AO7 (K144).
To determine which lysine residues within the RING
finger are required for the sumoylation of Mdm2, we
mutated the respective amino acids, generating three
mutants: K1 (K446R), K2 (K453R), and K3 (K465,466,
468,469,472R). Coexpression of HA-SUMO-1 and the
lysine-mutated forms of Mdm2 revealed that K2 and K3
exhibit the same mobility as the wild-type (wt) form of
Mdm2, although expressed to somewhat lower levels.
Conversely, the K1 mutant of Mdm2 migrated as a 75
kDa protein (Figure 2A, middle panel). The latter resem-
bles one of the endogenously expressed Mdm2 species
(Figure 1A) and may represent a nonsumoylated form
of Mdm2. These data imply that the exogenously ex-
Figure 2. Mutation of Lys-446 in Mdm2 Abolishes SUMO-1 Conju-pressed wt Mdm2 is efficiently sumoylated, whereas the
gationK1 mutant is not. Furthermore, analysis of Flag immuno-
(A) 293T cells were transfected with the indicated Flag-tagged Mdm2precipitates by immunoblotting with HA antibody re-
constructs and HA-SUMO-1. WCE were immunoprecipitated with
vealed that the K1 mutant is not conjugated with SUMO-1 antibodies indicated in the figure. The two bottom panels verify
in vivo (Figure 2A, upper panel). Thus, Lys-446 is the expression of the respective exogenously expressed constructs.
major sumoylation site on Mdm2. These findings also The top panel shows conjugation of wt Mdm2 as well as K1 (K446R),
K2 (K453R), and K3 (K465,466,468,469,472R) mutants to SUMO-1.demonstrate that mutations on other lysines within the
(B) Purified GST-tagged Mdm2 forms were sumoylated in vitro usingRING finger domain do not significantly impair Mdm2
in vitro translated 35S-labeled SUMO-1. The MW of the sumoylatedsumoylation, although we cannot exclude the possibility
Mdm2 is 120 kDa, due to the GST moiety. After the sumoylation
that residual sumoylation may occur at the lysine resi- reaction, GST-bound proteins were separated on SDS-PAGE and
dues outside of the RING finger. visualized by Coomassie staining (bottom panel). Upper panel
We directly assessed the sumoylation of Mdm2 in shows an autoradiograph of sumoylated Mdm2 forms. Efficient su-
moylation of Mdm2 was seen with the wt, K2, or K3 mutants butvitro. Bacterially expressed wt or mutant forms of Mdm2
not with the K1 mutant form or in the absence of SUMO-1. Reducedwere incubated with purified Aos1/Uba2, Ubc9, and in
sumoylation was seen in the absence of Ubc9 because of the pres-vitro translated immunopurified 35S-labeled SUMO-1 fol-
ence of minute amounts of the Ubc9 in the wheat germ extract used
lowed by SDS-PAGE and autoradiography (Figure 2B, to perform in vitro translation.
upper panel) or Coomassie Blue staining (Figure 2B,
lower panel). As evident from both the 35S-detected sig-
nal and the mobility of Mdm2 proteins, SUMO-1 was
lane 3 versus lane 4). This result demonstrates that Lys-conjugated with the wt Mdm2, as well as with the K2
446 serves as a major site for Mdm2 self-ubiquitination,and the K3 forms, but not with the K1 mutant. These
although we cannot rule out residual ubiquitination ofdata provide direct evidence for Mdm2 sumoylation at
other lysines within Mdm2 and/or GST moieties. To-Lys-446, which is similar to one of the major PML sumoy-
gether with the data presented in Figure 2, our findingslation sites.
suggest that SUMO-1 may compete with ubiquitin for
conjugation at Lys-446.
We next examined whether SUMO-1 modification al-Sumoylation of Mdm2 Inhibits Its Self-Ubiquitination
To investigate whether SUMO-1 and ubiquitin utilize a ters Mdm2 self-ubiquitination by performing the sumoy-
lation reaction prior to in vitro ubiquitination. SUMO-1similar conjugation site, we carried out an in vitro ubiqui-
tination reaction of the wt or K1 mutant forms of Mdm2. modification of Mdm2 was performed with purified bac-
terially expressed components, including SUMO-1,Incubation of Mdm2 proteins with E1, E2 (UbcH5b), 32P-
ubiquitin, and ATP resulted in detectable ubiquitination Aos1/Uba2, and Ubc9. As shown in Figure 3A, sumoyla-
tion of the wt Mdm2 efficiently decreased the degree ofof wt Mdm2 but not of the K1 Mdm2 mutant (Figure 3A,
Cell
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Mdm2 self-ubiquitination (Figure 3A, lane 1 versus lane
3). The efficiency of Mdm2 sumoylation under these
conditions was verified by slower migration of SUMO-
1-Mdm2 (Figure 3A, lower panel). Taken together, these
data demonstrate that Lys-446 serves as the primary
ubiquitination site on Mdm2 and that Mdm2 sumoylation
attenuates its self-ubiquitination in vitro.
Lysine 446 Is Required for Mdm2 Ubiquitination
and Degradation In Vivo
We next examined the role of Lys-446 in Mdm2 ubiquiti-
nation in vivo. Expression of Flag-tagged Mdm2 and
HA-tagged ubiquitin in 293T cells followed by Flag im-
munoprecipitation and anti-HA antibody analysis en-
abled the detection of ubiquitinated wt Mdm2 (Figure
3B). In contrast, K446R mutant was not ubiquitinated.
These observations establish that Lys-446 is required
for Mdm2 ubiquitination in vivo.
To determine whether self-ubiquitination of Mdm2 at
Lys-446 is required for Mdm2 degradation in vivo, we
measured Mdm2 half-life. 35S-pulse-chase labeling ex-
periments revealed that the 90 kDa form of Mdm2 is
more stable compared with the 75 kDa form of Mdm2
(Figure 3C). Whereas the half-life of the K1 form is around
2 hr, the p90 sumoylated form of Mdm2 exhibits a half-
life of less than 1 hr as compared with a half-life of less
than 30 min for the non-SUMO-1-modified p75 form of
Mdm2. Treatment of the cells with proteasome inhibitor
lactacystin prolonged the half-life of both p75 and p90,
whereas the half-life of the K1 remained unchanged
(Figure 3C). These observations further substantiate that
conjugation of SUMO-1 to Mdm2 stabilizes Mdm2 by
preventing its self-ubiquitination. It should be noted that
since the Mdm2 of z90 kDa is sumoylated (Figures 1±2)
and its direct ubiquitination may be impaired (Figure 3A),
it is likely that removal of SUMO-1 by sentrin-specific
protease1-like enzymes occurs prior to Mdm2 ubiquiti-
nation. In this case, the difference in the kinetics of p90
Figure 3. Sumoylation at Lys-446 of Mdm2 Abolishes Its Self-Ubi-form of Mdm2 and K1 degradation is probably underesti-
quitination and Increases Its Stabilitymated. Together with the data presented in Figure 3B,
(A) Wt or K1 mutant forms of Mdm2 were subjected to the sumoyla-these results suggest that Lys-446 is required for Mdm2
tion reaction using purified SUMO-1, Aos1/Uba2, and Ubc9 as de-ubiquitination and degradation in vivo.
tailed in the Experimental Procedures. SUMO-1- (or mock)-modified
forms of Mdm2 were then subjected to the self-ubiquitination assay
Mdm2 Sumoylation Does Not Affect Its using 32P-ubiquitin in the presence of purified E1 and E2. Following
Association with p53 the ubiquitination reaction, glutathione bead-coupled proteins were
washed, and proteins were separated on 8% SDS-PAGE. The lowerWe next determined whether SUMO-1 conjugation to
panel depicts Mdm2 protein visualized by Coomassie staining. TheMdm2 affects Mdm2 binding to p53. In its sumoylated
upper panel shows an autoradiograph of 32P-ubiquitin conjugatedform, Mdm2 is as efficient in its association with p53 as
to the respective Mdm2 forms.
the mutant form, as revealed by immunoprecipitation of (B) 293T cells were transfected with the wt or K1 forms of Mdm2
Mdm2 with antibodies to p53, or vice versa (Figure 4A). and HA-Ub. WCE was subjected to immunoprecipitation using
The association between p53 and Mdm2 could be identi- monoclonal antibodies to the Flag-tag. The lower panel shows ex-
pression level of the transfected Mdm2 forms. The upper panelfied using antibodies to either the amino or the carboxyl
depicts poly-HA-Ubiquitin chains conjugated to the respectiveterminus of Mdm2, thus excluding the presence of a
Mdm2 forms.spliced Mdm2 form (Perry et al., 2000) in this complex.
(C) p53/Mdm2 double null cells were transfected with the wt or K1
Each of the Mdm2 forms tested was capable of associat- forms of Mdm2 and 24 hr later were subjected to pulse chase label-
ing with p53 in vitro as evident from coimmunoprecipita- ing with 35S-methionine in the absence or presence of lactacystin
tion of in vitro translated proteins (Figure 4B). Forced (25 mM) as indicated in the figure. Proteins prepared at the indicated
time points were immunoprecipitated using monoclonal antibodiesexpression of p53 and wt or the K1 forms of Mdm2 in
to Mdm2 followed by autoradiography. The upper part of the figurep53/mdm2 double null cells also enabled the detection of
depicts analysis of the wt Mdm2-transfected cells whereas the lowerefficient association between p53 and the wt (sumoylated
part shows analysis of the K1-expressing cells.
in cells) or K1 (non-SUMO-1-modified) forms of Mdm2
(Figure 4C). These results suggest that SUMO-1 modifica-
tion does not affect Mdm2 association with p53.
SUMO Modification and Mdm2 E3 Ligase Activity
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with p53, we have examined the significance of Mdm2
self-ubiquitination in the Mdm2-mediated degradation
of p53. To this end, we compared the effects of the wt
Mdm2 and the K1 mutant on p53 accumulation in a
cotransfection assay (Haupt et al., 1997; Kubbutat et
al., 1997). p53/Mdm2 double null cells (Jones et al., 1995)
were used to exclude the influence of endogenous
Mdm2. Forced expression of the wt or the K1 forms of
Mdm2 in these cells led to a dose-dependent decrease
in the levels of p53 protein. Nevertheless, when com-
pared with the wt form of Mdm2, five times lesser
amounts of K1 expression construct were required to
achieve the same decrease in the level of p53 (0.5 versus
2.5 mg; Figure 5A, upper panel). This result indicates
that the Mdm2 mutant defective in self-ubiquitination is
more efficient in promoting p53 degradation in vivo than
the wt Mdm2. Since, under the conditions of forced
Mdm2 expression used in these experiments, the levels
of K1 and wt forms of Mdm2 were similar (Figure 5A,
lower panel), we cannot explain the enhanced activity
of K1 by merely the accumulation of a more stable K1
protein. Therefore, these data also suggest that Mdm2
self-ubiquitination is likely to be detrimental to Mdm2's
ability to ubiquitinate p53.
Sumoylation Increases the Ability of Mdm2
to Ubiquitinate p53
To directly assess the effect of Mdm2 ubiquitination on
its ability to target the degradation of p53, we performed
the Mdm2 self-ubiquitination reaction prior to adding
Mdm2 to p53 ubiquitination assay. In vitro ubiquitination
reactions were carried out using the purified E1, E2
(UbcH5b), Mdm2 (as the source for E3 ligase), and affin-
ity-purified HA-tagged p53 expressed in Sf9 insect cells.
In this two-step reaction, we enabled efficient self-ubi-
quitination of Mdm2 before addition of p53 as a sub-
strate to assay Mdm2-targeted ubiquitination. Analysis
of p53 ubiquitination (performed with antibodies to HA-
tagged p53, which enabled distinguishing p53 fromFigure 4. Mdm2 Sumoylation Does Not Affect Its Association with
p53 Mdm2 ubiquitination) revealed that in its ubiquitinated
(A) The association of Mdm2 with p53 is not affected by its sumoyla- form Mdm2 is less efficient in mediating the ubiquitina-
tion. Immunoprecipation of p53 (pAb421) or of Mdm2 (2A10 to C- tion of p53 (Figure 5B).
and N20 to N-terminal domains) followed by immunoblot analysis We have next assessed the effect of Mdm2 sumoyla-
using either of the Mdm2 antibodies (upper panel) or p53 antibodies tion on its ability to target the ubiquitination of p53.
(lower panel) identified the association of p53 with Mdm2 in its
Whereas Mdm2 mediated noticeable p53 ubiquitinationSUMO-1-modified form and in its nonsumoylated form.
(which was dependent on the presence of E1, E2, ubiqui-(B) Mdm2 in its wt or K1 forms associates with p53 in vitro. In vitro
tin, and ATP; Figure 5B; data not shown), there was atranslated, 35S-labeled, Flag-tagged Mdm2 wt or K1 forms were
incubated with HA-tagged p53 followed by immunoprecipitation remarkable increase in the degree of p53 ubiquitination
with antibodies to either p53 (HA) or Mdm2 (Flag). Immunopurified by SUMO-1-modified Mdm2 (Figure 5C). An increased
material was separated on SDS-PAGE and subjected to autoradiog- ubiquitin ligase activity of the K1 mutant correlates with
raphy. Immunoprecipitations identified both the target and associ- its elevated ability to degrade p53 in vivo (Figure 5A).
ated protein, respectively, as indicated by arrows on the right panel.
Sumoylated Mdm2 was as efficient in p53 ubiquitination(C) Wt or K1 forms of Mdm2 associate with p53 in vivo. Forced
as the K1 mutant of Mdm2, which does not exhibit self-expression of Flag-tagged Mdm2 wt or K1 and HA-tagged p53 in
ubiquitination. These data suggest that whereas ubiqui-Mdm2/p53 double null cells was followed by immunoprecipitation
and immunoblot analysis with the antibodies indicated in the figure. tination of Mdm2 impairs its ubiquitin ligase activity,
Mdm2 sumoylation at Lys-446 preserves Mdm2 ligase
activity for p53 ubiquitination by blocking the self-ubi-
Mdm2 K446R, which Is Not Capable of Self- quitination of Mdm2 E3 ubiquitin ligase.
Ubiquitination, Is More Efficient than Wt
Mdm2 in Promoting p53 Degradation Mdm2 K446R Is More Efficient than Wt Mdm2
Mdm2 elicits the ubiquitin ligase activities toward itself in Inhibition of p53-Induced Apoptosis
as well as toward p53. Given the observations that To examine the biological consequences of accelerated
Mdm2 sumoylation attenuates its self-ubiquitination and p53 degradation by mutant Mdm2, deficient in self-ubi-
quitination, we compared the abilities of the K1 andprolongs its half-life but does not affect its association
Cell
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Figure 5. Mdm2 Sumoylation or Mutation on Lys-446 Increases p53 Ubiquitination and Degradation and Decreases p53 Ability to Mediate
Apoptosis
(A) Mdm2/p53 double null cells were transfected with p53 and increasing amounts of the wt or the K1 forms of Mdm2 as indicated. WCE was
immunoprecipitated using monoclonal p53 antibodies. The lower panel shows expression levels of wt or K1 forms of Mdm2 detected by
monoclonal Mdm2 antibodies. The upper part of the figure shows the relative decrease in p53 expression levels upon Mdm2 (wt versus K1)
expression.
(B) Ubiquitinated Mdm2 is less efficient in targeting the ubiquitination of p53. Bacterially expressed Mdm2 (3 mg) was subjected to in vitro
ubiquitination (self-ubiquitination) in the presence of E1 (45 ng), E2 UbcH5b (1.5 mg), and ubiquitin (3 mg; SIGMA) and 2 mM ATP in ubiquitination
buffer for the 0, 2, or 3 hr (to ensure efficient self-ubiquitination) as indicated in the figure. To monitor the degree of Mdm2's ability to target
the ubiquitination of p53, equal amounts of the self-ubiquitinated Mdm2 were extensively washed with TBS/0.5% Triton X-100 before being
incubated with bacculovirus-expressed and purified form of HA-tagged p53 for 2 hr in the presence of E1, E2, and ubiquitin. The degree of
p53 ubiquitination was monitored via immunoblot analysis using antibodies to HA.
(C) Wt or K1 mutant forms of GST-Mdm2 (1 mg) were sumoylated (in the presence of purified E1 [Aos1/Uba2; 15 ng], E2 [Ubc9; 0.5 mg] and
SUMO-1 [1 mg]) or mock treated before incubation for 1 hr with WCE (1 mg) prepared from 293T cells that overexpress exogenous forms of
HA-p53. GST-Mdm2-p53-bound beads were washed with TBS/0.5% Triton X-100 to minimize nonspecific binding before initiating the in vitro
ubiquitination reaction in the presence of E1 (15 ng), E2 UbcH5b (0.5 mg), and ubiquitin (1 mg; SIGMA) and 2 mM ATP in ubiquitination buffer.
Proteins were separated on 10% SDS-PAGE. The ubiquitinated HA-p53 was detected by monoclonal HA-antibodies. Similar observations
were made using HA-tagged p53 that was purified from bacculovirus-expressing Sf9 cells (data not shown).
(D) DNA fragmentation analysis of Mdm2/p53 double null cells cotransfected with wild-type p53, increasing concentrations of wt, or K1 forms
of Mdm2, and GFP plasmids. Percent of apoptotic GFP-positive cells is indicated in the figure.
wt forms of Mdm2 to inhibit p53-mediated apoptosis. more efficient in inhibiting p53-mediated programmed
cell death, possibly because of the accelerated degra-Coexpression of wt or K1 forms of Mdm2 in Mdm2/p53
double null cells resulted in a dose-dependent decrease dation of p53.
in the apoptosis induced by forced expression of p53.
When compared with wt Mdm2, the K1 mutant, which Radiation Decreases the Degree
of Mdm2 Sumoylationis protected from self-ubiquitination, elicited a greater
decrease in degree of cell death (Figure 5D). This finding Stabilization of p53 in response to stress and DNA dam-
age is imperative for its ability to coordinate the cellularsuggests that abolished self-ubiquitination renders Mdm2
SUMO Modification and Mdm2 E3 Ligase Activity
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Figure 7. Model for the Regulation of Mdm2 Ubiquitin-Ligase Activ-
ity by SUMO-1
Mdm2 is subjected to either ubiquitination or sumoylation. When
self-ubiquitinated, the ubiquitin ligase activity of Mdm2 for p53 is
impaired. Upon SUMO-1 conjugation, Mdm2 is protected from ubi-
quitination and elicits increased ubiquitin ligase activity, as reflected
in increased ubiquitination and degradation of p53.
pared from UV-treated cells were tested for their ability
to mediate Mdm2 sumoylation in vitro. When compared
with proteins prepared from nontreated cells, the pro-
teins derived from UV-treated cells were less efficient
in eliciting Mdm2 sumoylation (Figure 6A). These obser-
Figure 6. Mdm2 Sumoylation Is Reduced after Cell Exposure to vations suggest that degree of Mdm2 sumoylation is
Radiation reduced upon UV-irradiation. Mdm2 that has been sub-
(A) Proteins prepared from control (-UV) or 2 hr after UV-irradiation jected to sumoylation in the presence of proteins from
were incubated with bacterially expressed Mdm2 and in vitro trans- UV-treated cells also elicited a less efficient ubiquitina-
lated 35S-labeled SUMO-1 under conditions required to enable
tion of p53 than proteins prepared from sham-treatedMdm2 sumoylation (for 1 or 2 hr as indicated in the figure). The
cells (data not shown).degree of SUMO-1 conjugation was monitored via autoradiography
To further assess the changes to Mdm2 sumoylationof the SDS-PAGE (upper panel), whereas the amount of Mdm2 in
its respective forms was visualized via Coomassie blue staining in response to radiation, we have monitored the expres-
(lower panel). Compare changes between control and UV treatment sion levels of the SUMO-1-modified Mdm2, the nonsu-
at the same time point, respectively. moylated form of Mdm2, and p53 in proteins prepared
(B) Normal human fibroblasts were treated with sham, UV, or X-rays
from UV- or X-ray-treated cells. A clear time- and dose-at indicated doses in the presence of proteasome inhibitor (MG132,
dependent decrease in the amount of SUMO-1-modified40 mM, for 3 hr before protein preparation). Proteins, prepared at
Mdm2 after exposure to either UV or X-rays was seenthe indicated time points after exposure, were immunoprecipitated
with antibodies to Mdm2 (IF2, which were used in this experiment, both in immunoprecipitation of Mdm2 followed by
rather than 2A10 antibodies used in former experiments, since the SUMO-1 Western (Figure 6B, upper panel) and in straight
latter do not recognize Mdm2 after exposure to radiation) and sub- immunoblot analysis of 90 kDa Mdm2 (Figure 6B, middle
jected to immunoblot analysis using antibodies to SUMO-1 (upper
panel). Immunoblot analysis of Mdm2 expression usingpart of the figure). Middle part of the figure depicts analysis of the
proteins prepared after UV or X-ray treatment in thesame membrane following its incubation with antibodies to Mdm2.
presence of proteasome inhibitors (to preserve the non-Lower part of the figure shows immunoblot of p53 in extracts (100
mg) prepared from cells subjected to the same treatments yet in the sumoylated form of Mdm2) revealed a shift from the
absence of the proteasome inhibitor. sumoylated to the nonsumoylated forms of Mdm2, in a
time- and dose-dependent fashion (Figure 6B, middle
panel). These results suggest that DNA damage, in thestress response. Under these circumstances, increased
p53 stability has been attributed, in part, to its dissocia- form of radiation, effectively diminishes the degree of
Mdm2 sumoylation in a dose- and time-dependent man-tion from Mdm2 (Shieh et al., 1997; Fuchs et al., 1998).
The current finding of Mdm2 sumoylation, and its effect ner. The decrease of Mdm2 sumoylation coincided with
an increased level of p53 expression (Figure 6B, loweron Mdm2 E3 ligase activity toward p53, points to an
additional layer of regulation, which is independent of panel), suggesting that the regulation of SUMO-1 modifi-
cation of Mdm2 may play a role in p53 stabilization inMdm2 dissociation from p53. Given the effect of sumoy-
lated Mdm2 on p53 ubiquitination, we determined response to DNA damage. The temporal decrease in the
amount of SUMO-1-conjugated Mdm2 points to one ofwhether DNA damage, which is among the best charac-
terized stimuli that increase p53 stability, alters the rela- the mechanisms by which p53 is no longer targeted by
Mdm2 for ubiquitination in response to DNA damage.tive amount of SUMO-1-modified Mdm2. Proteins pre-
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Discussion as an z90 kDa protein (Chen et al., 1993, 1996). Our
experiments suggest that the nonsumoylated form of
A common characteristic of RING finger proteins that Mdm2, which was bound to p53 and was recognized
exhibit ubiquitin ligase activity is that they are capable by amino-terminal Mdm2 antibodies, is not a spliced
of self-ubiquitination (Lorick et al., 1999; Fang et al., form of Mdm2, which lacks N-terminal sequences (Perry
2000; Honda and Yasuda, 2000). While it is conceivable et al., 2000). Given that sumoylation protects the Mdm2
that self-ubiquitination is required to limit the duration protein from degradation, SUMO-1-modified Mdm2 is
and magnitude of ubiquitin ligase output, the mecha- expected to be the more abundant Mdm2 form. That a
nism distinguishing self-ubiquitination from the ubiquiti- large portion of Mdm2 molecules are sumoylated further
nation of the target substrate has long been sought. emphasizes the biological significance of SUMO-1 mod-
Such a mechanism would have been expected to pro- ification for the Mdm2 protein.
vide a window of opportunity for substrate ubiquitination Our findings demonstrate that sumoylation resulted
before self-destruction takes place. in the inhibition of Mdm2 self-ubiquitination, thus provid-
Here, we demonstrate that self-ubiquitination of ing the mechanism that enabled us to distinguish be-
Mdm2 at Lys-446 within its RING finger domain impairs tween substrate ubiquitination and self-ubiquitination.
Mdm2 ubiquitin ligase activity and ability to ubiquitinate Accordingly, duration of protein sumoylation is ex-
p53. We also show that conjugation of the SUMO-1 pected to reflect the time frame during which the ubiqui-
ubiquitin-like protein to the same lysine residue abro- tination of Mdm2 targets (such as p53) occurs. A tempo-
gates Mdm2 self-ubiquitination and therefore preserves ral decrease in Mdm2 sumoylation occurs in response
Mdm2 ubiquitin ligase activity, resulting in concomi- to DNA damage and is inversely correlated with the
tantly increased efficiency of ubiquitination of its major elevated levels of p53. Attenuated Mdm2 sumoylation
substrate, p53 (Figure 7). Although the abilities of su- is likely to explain why Mdm2 is no longer capable of
moylated Mdm2 and self-ubiquitination-deficient K1 mediating the efficient ubiquitination of p53 in response
mutant to ubiquitinate p53 were similar, we cannot rule to DNA damage, in addition to decreased p53-Mdm2
out the possibility that in addition to preventing self- binding (Shieh et al., 1997; Fuchs et al., 1998).
ubiquitination, sumoylation elevates Mdm2 activity by Maintenance of a sumoylated substrate is expected
another mechanism. Our data provide additional evi- to be regulated by the balance between Mdm2 sumoy-
dence for the important role of ubiquitin-like proteins in lation and removal of SUMO-1 by the desumoylating
the modulation of E3 ubiquitin ligase activities. Conjuga- enzymes, including the sentrin-specific protease 1
tion of Cullins with the ubiquitin-like protein Nedd8/ (SENP1), which is distantly related to the yeast Smt3-
RUB1 is implicated in the biological activities of other specific protease ULP1 (Li and Hochstrasser, 1999;
RING finger-based E3 ubiquitin ligases such as SCF- Gong et al., 2000). Regulation of Mdm2 sumoylation may
ROC1 and VCB-Cul2-ROC1 (Lammer et al., 1998; Ka- also be affected by Mdm2 phosphorylation as well as
mura et al., 1999; Hori et al., 1999; Liakopoulos et al., by some of its associated proteins, including p14ARF,
1999). Like Mdm2 sumoylation, Nedd8/RUB1 conjuga- p300, pRb, and E2F1.
tion is also capable of activating the ability of SCF/ The consequences of Mdm2 sumoylation, as shown
bTgCP to ubiquitinate IkBa (Read et al., 2000) this modi- in this study, are reflected in increased ubiquitination
fication has yet to be identified. and degradation of p53 and the diminished p53 ability to
Sumoylation of PML or Sp100 proteins was reported elicit programmed cell death, which results in attenuated
to result in nuclear localization within PML bodies (Du- activities of this tumor suppressor protein. Accordingly,
prez et al., 1999; Strensdorf et al., 1999). Subcellular sumoylation is likely to play a key role in Mdm2's ability
localization of Mdm2 is unlikely to be affected by its to elicit its oncogenic activities.
sumoylation since the localization of the K1 mutant that Sumoylation of the Mdm2 target substrate p53 was
cannot undergo SUMO-1 modification did not differ from
shown not to affect p53 stability and was found on only
the localization of the wt protein (data not shown). This
a small portion of p53 molecules (Gostissa et al., 1999;
finding suggests that protein sumoylation may result in
Rodriguez et al., 1999), suggesting that SUMO-1 modifi-multiple biological outcomes, varying with the nature of
cation of Mdm2 may have greater implications for thethe sumoylated protein.
biological activities of p53.In the case of Mdm2, SUMO-1 modification competes
All in all, our findings that Mdm2 sumoylation in-with Mdm2 ubiquitination for the major conjugation site,
creases its ubiquitin ligase activities while protectingLys-446. It was previously shown that similar competi-
Mdm2 from self-ubiquitination provide an important ex-tion between sumoylation and ubiquitination occurs at
ample of the contribution of SUMO-1 modification tothe Lys-21 of IkBa (Desterro et al., 1998). Although re-
the maintenance of intrinsic E3 ubiquitin ligase activity.sembling the case of IkBa in the role of the active inter-
play between sumoylation and ubiquitination dictating
the degree of Mdm2 stability, SUMO-1 modification of Experimental Procedures
Mdm2 has major consequences for its activity as ubiqui-
Expression Vectorstin ligase. Moreover, unlike the sumoylation of IkBa,
Human wt Mdm2 cDNA was amplified by PCR (HiFi Taq polymerase,which was shown to occur in a small percentage of IkBa
GIBCO) and unidirectionally cloned, with the addition of two N-ter-molecules (Desterro et al., 1998), SUMO-1 modification
minal Flag-tags, between the EcoRI and BamHI sites of pcDNA3.
of Mdm2 was found in almost 100% of exogenously Bacterial expression vector of GST-Mdm2 (in pGEX-4T-1) was kindly
expressed proteins and is largely noted among the en- provided by Dr. A. Weissman. Wt Mdm2 in pcDNA3 or pGEX-4T-1
dogenous Mdm2 species (as represented by the 90 kDa was used as a backbone for generating the site-directed mutagene-
sis (Quick Change, Stratagene) to substitute lysines 446 (K1), 453MW band). Indeed, Mdm2 has often been referred to
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(K2) or 465, 466, 468, 469, 472 (K3) for arginines. The integrity of by Laemmli sample buffer, separated by 10% SDS-PAGE, and ana-
lyzed by immunoblotting using monoclonal HA-antibody.the resulting constructs was verified by sequencing. HA-tagged p53
expression vector was previously described (Fuchs et al., 1998).
pcDNA3-HA-SUMO-1 expression vector was kindly provided by Dr. In Vivo Half-Life Measurements
R. Hay (Rodriguez et al., 1999). PCMV-HA-Ub expression construct p53/Mdm2 double null cells were transfected with wt or K1 forms
was a gift from Dr. D. Bohmann (Treier et al., 1994). of Mdm2 expression vectors (4 mg). 35S-methionine (1 mCi) was
added to the cell cultures 24 hr after transfection for 5 hr (pulse)
followed by chase (2 mM cold methionine) for the indicated timeCells
points. Protein extracts (1 mg) were used for immunopurification of293T, adenovirus-transformed human embryo kidney cells (a kind
Mdm2 using mixture of monoclonal antibodies (2A-10/IF2). Immuno-gift of Dr. E. Spanopoulou), p53/Mdm2 double null cells (kindly pro-
precipation Mdm2 was washed, separated on 10% SDS-PAGE, andvided by Dr S. Jones), and normal human fibroblasts (a kind gift of
analyzed by autoradiography.Dr. H. Tahara) were maintained in DMEM (GIBCO), supplemented
with 10% heat-inactivated fetal bovine serum and antibiotics in 5%
In Vivo Sumoylation/UbiquitinationCO2. Transfections were performed by the calcium phosphate pre-
Cells were transfected with Mdm2 constructs and cDNAs encodingcipitate technique for 293T cells and by lipofection (Lipofectamin-
either HA-tagged SUMO-1 or HA-tagged ubiquitin to analyze sumoy-Plus, GIBCO) for p53/Mdm2 null cells. The medium was changed 6
lation or ubiquitination, respectively. Harvested cell pellets werehr after transfection, and cells were harvested 24 hr later.
lysed by incubation with two volumes of 2% SDS in TBS (10 mM
Tris-HCl [pH 8.0] and 150 mM NaCl) at 958C for 10 min. Eight volumes
Antibodies of 1% Triton-X-100 in TBS were added, and lysates were sonicated
Monoclonal antibodies against Flag- and HA-epitopes were pur- for 2 min. The solution was incubated for 30 min at 48C with Protein
chased. (M2, SIGMA, and HA11, BabCo). Antibodies (monoclonal) A/G beads (GIBCO) and clarified by 30 min centrifugation (14,000
against SUMO-1 were purchased (Zymed). Monoclonal antibodies rpm) at 48C. The protein concentration was determined by Bradford
2A10 (a gift from A. Levine), N20 (Santa Cruz), and IF2 (Oncogene) assay. For immunoprecipation, 500 mg of protein was incubated
were used for Mdm2 analysis. p53 detection was carried out using with respective antibodies at 48C overnight before Protein A/G beads
monoclonal pAb421 antibodies (Oncogene) and polyclonal FL393 (25 ml) were added for 2 hr. The beads were washed with 0.5 M LiCl
antibodies (SantaCruz). in TBS followed by two additional washes with TBS. Proteins were
loaded onto 10% SDS-PAGE, followed by immunoblot analysis with
In Vitro Conjugation of SUMO-1 the indicated antibodies and ECL detection (Amersham).
Glutathione beads (SIGMA) were used to purify bacterially ex-
pressed forms of GST-Mdm2 forms (wt, K1, K2, K3) as previously Apoptosis Assay
described (Lorick et al., 1999). Bacterially expressed purified Mdm2 Mdm2/p53 double null cells were transfected with Mdm2 constructs
(1±2 mg) proteins were incubated with either purified form of bacteri- (as indicated) and marker plasmid encoding Green Fluorescent Pro-
ally expressed SUMO-1 or with in vitro translated 35S-labeled SUMO-1 tein, pEGFP (1 mg). Twenty-four hours after transfection, cells were
(TNT, Promega), as indicated in the Results. To initiate SUMO-1 collected, fixed in 1% paraformaldehyde, treated with 70% ethanol,
conjugation to Mdm2, purified Aos1/Uba2 (15 ng) and Ubc9 (0.5 mg) washed with PBS, treated with DNase-free RNase A (1 mg/ml), and
were added to the reaction mix for 30 min at 378C in conjugation stained with propidium iodide ([PI] 40 mg/ml). DNA fragmentation
buffer (20 mM Hepes [pH 7.4], 5 mM MgCl2, 2 mM ATP, 10 mM analysis of GFP-positive cells (50,000 per measurement in tripli-
creatine phosphate, and 1 unit creatine phosphokinase). Bead- cates) was carried out on a flow cytometer (Becton Dickinson). The
bound SUMO-1-modified Mdm2 was either taken for subsequent percentage of cells to the left of the diploid G0/1 peak, characteristic
reaction (see p53 ubiquitination) or washed (33 TBS/0.5% Triton- of hypodiploid cells, was calculated as the percentage of apoptotic
X-100) before denaturation for 5 min at 958C in 33 Sample Buffer. cells.
Proteins were separated on 8% SDS-PAGE. The gel was stained
with Coomassie blue, dried, and exposed to X-ray film (Xomat, Acknowledgments
Kodak).
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National Institutes of Health grants CA55908 (Z. R.), CA80058 (Z. R.),treated with the respective buffers as control) by addition of the
and GM55059 (Z. Q. P.) is gratefully acknowledged.purified form of bacterially expressed SUMO-1 together with Aos1/
Uba2 and Ubc9 (see in vitro sumoylation reaction). Upon its SUMO-1
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